Delving into the Latest Updates on Nanjing Shunxin Pharmaceutical Co., Ltd. with Synapse

Overview

Basic Info

Introduction

Established in 2001 by Thailand's Charoen Pokphand Group and Jiangsu Province Agricultural Reclamation Group, Nanjing Shunxin Pharmaceutical Co., Ltd. is now a leading Chinese pharmaceutical company. It specializes in areas including cardiovascular, tumor, imaging, perioperative, digestive, and urological therapies. Guided by the notion that imitation stimulates innovation, the company invests heavily in its R&D team, fostering innovative products that rank among the top in China's generic drug consistency evaluations. The company is currently researching a lots of products including innovative drugs, biopharmaceuticals, sustained-release formulations, and specialized generic drugs.

Tags

Neoplasms

Skin and Musculoskeletal Diseases

Hemic and Lymphatic Diseases

Monoclonal antibody

Small molecule drug

Biosimilar

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	19
Hemic and Lymphatic Diseases	11
Immune System Diseases	10
Infectious Diseases	3
Endocrinology and Metabolic Disease	3

Top 5 Drug Type	Count

Monoclonal antibody	10
Small molecule drug	6
Biosimilar	5
Recombinant coagulation factor	2
Bispecific antibody	2

Top 5 Target	Count

HER2(Receptor tyrosine-protein kinase erbB-2)	4
IL-33R(Interleukin-1 receptor-like 1)	1
CD38(Lymphocyte differentiation antigen CD38)	1
Bcl-2(Apoptosis regulator Bcl-2)	1
AR(Androgen Receptor)	1

[Main purpose] ? To evaluate the pharmacokinetic (PK) similarity of TQB2709 injection and Zhaoke® in healthy male volunteers after a single intravenous administration; [Secondary purpose] ? To evaluate the safety, tolerability and immunogenicity of TQB2709 injection and Zhaoke® in healthy male volunteers after a single intravenous administration.

Start Date25 Jun 2024

Sponsor / Collaborator

Nanjing Shunxin Pharmaceutical Co., Ltd.

CTR20241278 / Active, not recruitingPhase 1

评估健康成年受试者多次给药TQB3616胶囊安全性、耐受性的I期临床试验.

[Translation] A phase I clinical trial to evaluate the safety and tolerability of multiple doses of TQB3616 capsules in healthy adult subjects.

评估健康成年受试者多次给药TQB3616胶囊后的安全性、耐受性。评估健康成年受试者多次给药TQB3616胶囊后的药代动力学。

[Translation]

To evaluate the safety and tolerability of TQB3616 capsules after multiple administration in healthy adult subjects. To evaluate the pharmacokinetics of TQB3616 capsules after multiple administration in healthy adult subjects.

Start Date11 Jun 2024

Sponsor / Collaborator

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

[+1]

CTR20241503 / RecruitingPhase 1

TQB2450注射液（20ml：600mg）在健康男性受试者中随机、双盲、单剂量、平行设计的药代动力学和安全性的相似性临床研究

[Translation] A randomized, double-blind, single-dose, parallel-designed pharmacokinetic and safety similarity clinical study of TQB2450 injection (20ml: 600mg) in healthy male subjects

主要目的：评价正大天晴药业集团南京顺欣制药有限公司新旧场地生产的TQB2450注射液在健康男性受试者单次静脉给药的药代动力学（PK）相似性。次要目的：评价正大天晴药业集团南京顺欣制药有限公司新旧场地生产的TQB2450注射液在健康男性受试者单次静脉给药的安全性、耐受性和免疫原性。

[Translation]

Primary objective: To evaluate the pharmacokinetic (PK) similarity of TQB2450 injection produced by the old and new sites of Nanjing Shunxin Pharmaceutical Co., Ltd., Chia Tai Tianqing Pharmaceutical Group, in healthy male subjects after a single intravenous administration. Secondary objective: To evaluate the safety, tolerability and immunogenicity of TQB2450 injection produced by the old and new sites of Nanjing Shunxin Pharmaceutical Co., Ltd., Chia Tai Tianqing Pharmaceutical Group, in healthy male subjects after a single intravenous administration.

Start Date15 May 2024

Sponsor / Collaborator

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

[+1]

100 Clinical Results associated with Nanjing Shunxin Pharmaceutical Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Nanjing Shunxin Pharmaceutical Co., Ltd.

Login to view more data

100 Deals associated with Nanjing Shunxin Pharmaceutical Co., Ltd.

Login to view more data

100 Translational Medicine associated with Nanjing Shunxin Pharmaceutical Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 27 Jul 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

IND Application

4

5

IND Approval

Phase 1 Clinical

7

5

Phase 2 Clinical

Phase 3 Clinical

2

3

NDA/BLA

Approved

5

4

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Rituximab biosimilar (Chia-tai Tianqing) ( CD20 )	CD20 positive Diffuse Large B-Cell Lymphoma More	Approved
Recombinant coagulation factor VIII(Chia Tai-Tianqing) ( F10 )	Hemophilia A More	Approved
Unecritinib ( ALK x ROS1 x c-Met )	Reactive oxygen species 1 positive non-small cell lung cancer More	Approved
Trastuzumab biosimilar (Chia-tai Tianqing) ( HER2 )	HER2 Positive Breast Cancer More	Approved
Benmelstobart ( PDL1 )	Extensive stage Small Cell Lung Cancer More	Approved